ArticleThe American journal of case reports2022
An Infant Presenting with Interstitial Lung Disease Diagnosed Later as Hunter Syndrome: A Case Report.
Article in The American journal of case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review.International journal of molecular sciences · 2024Pooled it
- Mucopolysaccharidosis Type II Screening, Diagnosis, and Management: A Literature Review and Practical Recommendations for Newborn Screening Programs and Health Care Providers to Support Families and Improve Outcomes.International journal of neonatal screening · 2026Review
- Nebulized and intravenous enzyme replacement therapy in mice with mucopolysaccharidosis type II.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Hunter syndrome is a multisystem metabolic inherited disease belonging to the large group of mucopolysaccharidoses (MPSs). Hunter syndrome is also known as MPS type II. Its association with respiratory symptoms has been well documented in the literature; however, it is uncommon that these patients initially present with diffuse lung disease and respiratory failure. Diffuse lung disease has a wide range of differential diagnoses that can overlap in some clinical and radiological aspects, making physicians struggle to quickly reach a final diagnosis. CASE REPORT We report a case of a full-term male infant who presented postnatally with progressive respiratory distress, hypoxemia, and radiologically-demonstrated ground-glass opacity and pneumothorax requiring mechanical ventilation and an extensive workup including CT scan of the chest, a flexible and rigid bronchoscopic examination of the airway with bronchoalveolar lavage, and whole-exome sequencing, which eventually resulted in a diagnosis of Hunter syndrome. After enzyme therapy was initiated, the patient showed marked improvement in clinical status and biological and imaging data and was weaned off oxygen a few months later. CONCLUSIONS The diagnostic approach for patients with diffuse lung disease is challenging and requires centers with expertise to reach a final diagnosis, especially in the presence of an unusual clinical presentation. The choice of the diagnostic approach can be influenced by factors such as the patient's critical condition, clinical presentation, imaging data, genetic analysis, and family decision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.